Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
n-Lorem Foundation
With
Massachusetts General Hospital
This is an interventional study to evaluate the safety and efficacy of treatment with an individualized antisense oligonucleotide (ASO) treatment in a single participant with CONDBA due to a pathogenic heterozygous missense gain-of-function mutation in UBTF
Age
Any age
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent/assent provided by the participant (when appropriate), and/or participant's parent(s) or legally authorized representative(s)
Ability to travel to the study site and adhere to study-related follow-up examinations and/or procedures and provide access to participant's medical records
Genetically confirmed CONDBA due to UBTF gene mutation
You may not be if
Participant has any condition that in the opinion of the Site Investigator, would ultimately prevent the completion of study procedures